NOX CEO interview on near complete NOX66 chemotherapy trial
Filed with ASX · · 2 pages · English
Story so far
Earlier from Noxopharm
- NOX CEO interview on Radiotherapy Clinical Programs
- St Vincents Hospital study passes first milestone
- DARRT-1 Clinical Study commences
- NOX raises $10.8 M to advance clinical program
- Evidence of Abscopal Responses in Patients
Later from Noxopharm
- NOX to present at American Society of Clinical Oncology
- End-of-Study Clinical Data shows benefit of NOX66
- Pre-Clinical data confirms Radio-Enhancing potential
- Release of DARRT-1 Preliminary Safety Data
- VEYONDA - Registered Trade Mark for NOX66
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm